Literature DB >> 12124807

Inflammation and cancer, the mastocytoma P815 tumor model revisited: triggering of macrophage activation in vivo with pro-tumorigenic consequences.

Caroline Kamate1, Samia Baloul, Sabine Grootenboer, Eric Pessis, Alain Chevrot, Micheline Tulliez, Carmen Marchiol, Mireille Viguier, Didier Fradelizi.   

Abstract

Subcutaneous in vivo injections of cells of the mastocytoma line P815 in syngenic DBA/2 mice induce locally fast growing solid tumors. These have been used extensively as a cancer model to analyze and manipulate the relationship between tumor cells and host's immune defenses. We report that progression of P815 tumors in vivo was accompanied by a burst (Days 5-7) of local inflammatory cells recruitment and angiogenesis observed histologically, corroborated in vivo by MRI with gadolinium, overtranscription of macrophage activation marker genes, secretion of TNF-alpha by regional lymph node cells and concomitant systemic inflammation. No substantial overtranscriptions of either VEGF or IL-10 or TGF-beta genes were observed. Induction of COX-2 gene was a late event. To establish a possible relationship between the tumor-induced local, regional and systemic increase of pro-inflammatory mediators and progression of tumors in vivo, we carried out experiments deliberately modulating the inflammatory status of the recipient animals. Pretreatment of recipient animals by i.p. injection of thioglycolate accelerated P815 tumor growth. At the opposite, treatment of mice with either a COX-1 + COX-2 inhibitor (aspirin, 1 mg/day/mouse) or a specific COX-2 inhibitor (celecoxib, 0.13 mg/day/mouse) for 2 weeks after injection of tumor cells, significantly reduced the size and growth rate of tumors compared to control mice. Experiments carried out in vitro indicated that peritoneal macrophages from untreated animals were strongly activated by live P815 cells and by P815 membrane preparations. The tumor-induced inflammatory reaction could establish a local micro environment favoring tumor progression. The P815 tumor model might be helpful to recognize important factors controlling host/tumor relationship. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12124807     DOI: 10.1002/ijc.10519

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Hypoxic Macrophage-Derived VEGF Promotes Proliferation and Invasion of Gastric Cancer Cells.

Authors:  Fei Ma; Bin Zhang; Sheqing Ji; Hongtao Hu; Ye Kong; Yawei Hua; Suxia Luo
Journal:  Dig Dis Sci       Date:  2019-05-17       Impact factor: 3.199

Review 2.  Serum amyloid A: an acute-phase protein involved in tumour pathogenesis.

Authors:  E Malle; S Sodin-Semrl; A Kovacevic
Journal:  Cell Mol Life Sci       Date:  2009-01       Impact factor: 9.261

3.  Increased immunogenicity to P815 cells modified with malondialdehyde and acetaldehyde.

Authors:  Michael J Duryee; Lynell W Klassen; Bonnie L Jones; Monte S Willis; Dean J Tuma; Geoffrey M Thiele
Journal:  Int Immunopharmacol       Date:  2008-04-28       Impact factor: 4.932

4.  The anti-breast cancer property of physcion via oxidative stress-mediated mitochondrial apoptosis and immune response.

Authors:  Luping Zhang; Ruitao Dong; Yu Wang; Longxiang Wang; Tian Zhou; Dongxu Jia; Zhaoli Meng
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503

5.  Content-based image retrieval of digitized histopathology in boosted spectrally embedded spaces.

Authors:  Akshay Sridhar; Scott Doyle; Anant Madabhushi
Journal:  J Pathol Inform       Date:  2015-06-29

6.  Design and Synthesis of New 1,3,5-Trisubstituted Triazines for the Treatment of Cancer and Inflammation.

Authors:  Boulos Zacharie; Shaun D Abbott; Jean-Simon Duceppe; Lyne Gagnon; Brigitte Grouix; Lilianne Geerts; Liette Gervais; François Sarra-Bournet; Valérie Perron; Nicole Wilb; Christopher L Penney; Pierre Laurin
Journal:  ChemistryOpen       Date:  2018-09-21       Impact factor: 2.911

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.